Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1038/s41564-021-00958-0

http://scihub22266oqcxt.onion/10.1038/s41564-021-00958-0
suck pdf from google scholar
34471255!ä!34471255

suck abstract from ncbi

pmid34471255      Nat+Microbiol 2021 ; 6 (10): 1219-1232
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Cellular host factors for SARS-CoV-2 infection #MMPMID34471255
  • Baggen J; Vanstreels E; Jansen S; Daelemans D
  • Nat Microbiol 2021[Oct]; 6 (10): 1219-1232 PMID34471255show ga
  • The coronavirus disease 2019 (COVID-19) pandemic has claimed millions of lives and caused a global economic crisis. No effective antiviral drugs are currently available to treat infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The medical need imposed by the pandemic has spurred unprecedented research efforts to study coronavirus biology. Every virus depends on cellular host factors and pathways for successful replication. These proviral host factors represent attractive targets for antiviral therapy as they are genetically more stable than viral targets and may be shared among related viruses. The application of various 'omics' technologies has led to the rapid discovery of proviral host factors that are required for the completion of the SARS-CoV-2 life cycle. In this Review, we summarize insights into the proviral host factors that are required for SARS-CoV-2 infection that were mainly obtained using functional genetic and interactome screens. We discuss cellular processes that are important for the SARS-CoV-2 life cycle, as well as parallels with non-coronaviruses. Finally, we highlight host factors that could be targeted by clinically approved molecules and molecules in clinical trials as potential antiviral therapies for COVID-19.
  • |Antiviral Agents/pharmacology/therapeutic use[MESH]
  • |COVID-19 Drug Treatment[MESH]
  • |COVID-19/*metabolism/virology[MESH]
  • |Host-Pathogen Interactions/drug effects[MESH]
  • |Humans[MESH]
  • |Peptide Hydrolases/metabolism[MESH]
  • |RNA, Viral/metabolism[MESH]
  • |Receptors, Virus/metabolism[MESH]
  • |SARS-CoV-2/drug effects/*physiology[MESH]
  • |Viral Proteins/metabolism[MESH]
  • |Virus Internalization/drug effects[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box